LongBio Pharma says China regulator accepts LP-003 BLA for seasonal allergic rhinitis

• LongBio Pharma’s China regulator accepted a BLA for LP-003 to treat seasonal allergic rhinitis.
• LP-003 is an anti-IgE antibody developed for allergic diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Longbio Pharma (Suzhou) Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260821-12293421), on August 20, 2026, and is solely responsible for the information contained therein.